• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer

Contact Us

LinkedIn

GlycoMimetics
MENU 
  • Home
  • About Us
    • Management Team
    • Board of Directors
    • Core Values
  • For Patients
    • Multiple Myeloma
    • Sickle Cell Disease
    • Acute Myeloid Leukemia (AML)
  • For Clinicians
    • Product Portfolio
    • Rivipansel (GMI-1070)
    • GMI-1271
    • GMI-1359
    • Galectin Inhibitors
    • Expanded Access
  • Technology & Publications
    • Scientific Publications
    • Intellectual Property
    • Platform
    • Research Programs
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Contact Us
  • Careers
    • Benefits
    • Core Values

Product Portfolio

rivenpansel-button

GMI-1271-button

GMI-1359-button

Primary Sidebar

  • Patient Information
  • For Clinicians

News & Events

  • GlycoMimetics Announces Pricing of Public Offering of Common Stock Tue, Mar 20, 2018
  • GlycoMimetics Announces Proposed Public Offering of Common Stock Mon, Mar 19, 2018
  • GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018 Wed, Mar 14, 2018
  • GlycoMimetics to Present at Four Investor Conferences This Month Wed, Mar 07, 2018

Click here for Events

Footer

GlycoMimetics © 2016. All rights reserved. GlycoMimetics, Inc. – info@glycomimetics.com – 240.243.1201

Sitemap | Contact Us | Website Design & Development by Graphic Beans